CORRIGENDUM

DOI: 10.3892/ijmm.2023.5303

Antiproliferative effect of alpinetin in BxPC-3 pancreatic cancer cells

JIAN DU, BO TANG, JINGWEN WANG, HONGTAO SUI, XUELI JIN, LIMING WANG and ZHONGYU WANG

Int J Mol Med 29: 607-612, 2012; DOI: 10.3892/ijmm.2012.884

Following the publication of the above article, an interested reader drew to the authors' attention that, for the western blots shown in Fig. 4 on p. 610, the two leftmost bands shown for the Bax data in Fig. 4A were strikingly similar to the two rightmost Mito Cyt C bands featured in Fig. 4C. The authors have checked their original data, and realized that these data were assembled incorrectly in this figure. The revised version of Fig. 4 is shown below, now featuring the correct Bax data in Fig. 4A. The authors confirm that the errors associated with this figure did not have any significant impact on either the results or the conclusions reported in this study, and are grateful to the Editor of *International Journal of Molecular Medicine* for allowing them the opportunity to publish this Corrigendum. Furthermore, they apologize to the readership of the Journal for any inconvenience caused.



Copyright © 2023 Du et al. This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) License.




Figure 4. The effect of alpinetin on the protein expression of Bcl-2 family members and XIAP and on the release of mitochondrial cytochrome c. BxPC-3 cells were treated with different concentrations (0, 20, 40, 60 and 80 µg/ml) of Alpinetin for 48 h. (A) The expression of Bcl-2, Bcl-xL, Bax and XIAP were determined by western blot analysis. (C) The expression of cytochrome c in mitochondria and cytoplasm were also examined by western blot analysis. (B and D) The western blot results were further analyzed using Gel-Pro Analyzer 4.0 software (*P<0.05). Results are representative of three independent experiments.